AHA Coding Clinic® for HCPCS - 2007 Quarter 2; FOR your INFORMATION
New HCPCS Codes for the reporting of immune globulin
Currently, liquid intravenous immune globulin products are reported with HCPCS code J1567 , Injection, immune globulin, IV, non-lyophilized (liquid), 500 mg. Effective July 1, 2007, this code will no longer be billable for Medicare. For non-Medicare reporting, it is important that you check with your respective payor for appropriate reporting instructions. Several new HCPCS codes will replace HCPCS code J1567 for the reporting of liquid intravenous immune globulin. The new codes are listed in Table 1. Additionally, effective July 1, 2007, new HCPCS codes were established for the reporting of Rhophylac® and HepaGam B™. These new HCPCS codes are listed...
Subscribe or sign in to view the full article.
Article Overview
This article explains a set of HCPCS changes related to immune globulin reporting and is aimed at coders, billers, and reimbursement staff who work with injectable biologic products. It covers the introduction of new HCPCS identifiers for specific products, the phase-out of prior reporting for Medicare in one area, and related billing notes tied to product type and route of administration. The article is useful for anyone who needs to track coding updates, payor-specific reporting practices, and CMS guidance affecting these drugs.
Why This Topic Matters
HCPCS code changes can affect claim submission, product reporting, and payer compliance. Understanding which products have new identifiers and when older reporting pathways change helps reduce denials and support accurate billing.
Article Sections
-
HCPCS updates for immune globulin products
Introduces the reporting changes for immune globulin products and the timing of the new HCPCS assignments. It also notes the broader context of Medicare and non-Medicare reporting.
-
Table 1
Lists newly established HCPCS identifiers for several liquid intravenous immune globulin products. The section presents the product groupings and their reporting categories.
-
Table 2
Lists newly established HCPCS identifiers for Rhophylac and HepaGam B. The section also includes notes about product-specific reporting circumstances and a related nonclassified coding reference.
What You Will Learn
- How this article addresses HCPCS reporting changes for immune globulin products
- Which types of products were added or updated in the HCPCS system
- What general billing and payor-related considerations are mentioned
- How CMS guidance is referenced in connection with the update
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement staff
- Practice administrators
- Healthcare compliance teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com